Market Valuation & Earnings Multiples
Market capitalization, P/E ratios, and enterprise value
Market Cap3.25B
Enterprise Value3.15B
DNTH
(NASDAQ)Dianthus Therapeutics, Inc.
$86.00-- (--)
Loading... - Market loading
Dianthus Therapeutics (DNTH) Key Statistics & Financial Metrics
Complete stock analysis with 40+ metrics: valuation ratios, profitability margins, financial health indicators, and dividend data.
Stock Valuation Metrics
Market value, earnings multiples, and pricing ratios
Price-Based Ratios
Valuation ratios based on stock price
Price/Sales (ttm)1569.68
Forward Price/Sales2242.40
Price/Book (mrq)6.48
Price/Tangible Book (mrq)6.48
Enterprise Value Ratios
EV-based valuation multiples
EV/Revenue1545.27
EV/EBITDA-17.74
EV/EBIT-22.42
EV/FCF-24.34
Stock Price
Current price, 52-week range, and moving averages
Current Price$86.00
1-Day Change0.76%
52-Week High$88.49
52-Week Low$13.37
52-Week Change402.44%
YTD Change113.10%
1-Year Change373.46%
50-Day MA$62.50
200-Day MA$39.56
Avg Volume (30 day)879.70K
Share Statistics
Outstanding shares, float, and per-share metrics
Shares Outstanding37.79M
Book Value per Share$13.06
Net Cash per Share$1.34
FCF per Share$-3.42
Analyst Price Targets & Consensus
Wall Street analyst ratings and 12-month price targets (90 days)
Price Target$128.90
Target Upside/Downside49.88%
Analyst ConsensusStrong Buy
Analyst Count10
Profitability & Financial Performance
Profit margins, return metrics, and earnings analysis
Profit Margins
Profitability margins across income statement
Gross Margin100.00%
EBITDA Margin (ttm)-8710.36%
EBIT Margin (ttm)-6891.36%
Operating Margin (ttm)-8739.34%
Pretax Margin (ttm)0.00%
Profit Margin (ttm)0.00%
FCF Margin (ttm)-6349.36%
Return on Investment Metrics
ROE, ROA, ROIC, and capital efficiency ratios
Return on Equity (ttm)0.00%
Return on Assets (ttm)0.00%
Return on Invested Capital (ttm)-24.98%
Return on Capital Employed (ttm)-28.05%
Income Statement (TTM)
Trailing twelve months revenue and earnings
Revenue2.04M
Gross Profit2.04M
Operating Income-177.93M
Pretax Income0.00
Net Income0.00
EBITDA-177.34M
EBIT-140.31M
Diluted EPS$0.00
Cash Flow (TTM)
Operating cash flow and free cash flow metrics
Operating Cash Flow-129.06M
Capital Expenditures213.00K
Free Cash Flow-129.27M
Growth Rates (YoY)
Year-over-year growth metrics
Revenue Growth-67.35%
Financial Health & Dividends
Balance sheet analysis, debt ratios, and dividend metrics
Assets & Cash
Total assets and cash positions
Total Assets (mrq)530.92M
Cash & Securities (mrq)51.09M
Net Cash (mrq)50.72M
Net Cash per Share$1.34
Debt & Liabilities
Liabilities, debt, equity, and working capital
Total Debt (mrq)1.39M
Working Capital (mrq)378.71M
Total Equity (mrq)493.40M
Book Value per Share$13.06
Liquidity & Leverage
Liquidity, leverage, and debt coverage ratios
Current Ratio (mrq)13.32
Quick Ratio (mrq)13.32
Debt/Equity (mrq)0.00
Dividend History & Payout Analysis
Dividend yield, payout ratios, and growth metrics
Dividend per Share (TTM)$0.00
Dividend Yield0.00%
Yield Metrics
Earnings, FCF, buyback, and shareholder yields
Earnings Yield0.00%
FCF Yield-4.05%
Buyback Yield-0.01%
Total Shareholder Yield-0.01%
Financial Health Scores
Risk assessment and quality metrics
Altman Z-Score50.21
Piotroski F-Score2/9
Frequently Asked Questions About Dianthus Therapeutics Statistics
What are the key financial metrics for DNTH?
Dianthus Therapeutics, Inc. (DNTH) statistics include 40+ financial metrics organized into valuation ratios (P/E, P/S, P/B, PEG), profitability margins (gross, operating, net), return metrics (ROE, ROA, ROIC), and financial health indicators. These are updated regularly based on the latest filings and market data.
What is DNTH's valuation analysis?
The valuation section covers market capitalization, earnings multiples like trailing and forward P/E, price-based ratios (P/S, P/B, Price/FCF), and enterprise value ratios (EV/EBITDA, EV/Revenue, EV/FCF). Compare these against sector averages to assess whether Dianthus Therapeutics is overvalued or undervalued.
How do I read DNTH's profitability ratios?
Dianthus Therapeutics's profitability is measured through profit margins (gross, EBITDA, operating, net) and return metrics (ROE, ROA, ROIC, ROCE). Higher margins indicate better cost control, while higher returns show efficient capital deployment. The income statement and cash flow sections provide the underlying revenue and earnings data.
What do DNTH's debt ratios indicate?
The financial health section shows Dianthus Therapeutics's leverage through debt-to-equity, debt-to-assets, debt-to-EBITDA, and debt-to-FCF ratios, plus liquidity via the current and quick ratios. Lower debt ratios and higher liquidity ratios generally indicate stronger financial stability and lower default risk.
What is DNTH's dividend analysis?
The dividend section covers Dianthus Therapeutics's dividend yield, payout ratios (earnings-based and FCF-based), year-over-year dividend growth, years of consecutive growth, ex-dividend and pay dates, and payment frequency. The yield metrics section also includes earnings yield, FCF yield, buyback yield, and total shareholder yield.